middle.news
How Orthocell’s PearlBone™ Deal Could Transform Bone Regeneration Markets
9:10am on Friday 16th of January, 2026 AEDT
•
undefined
Read Story
How Orthocell’s PearlBone™ Deal Could Transform Bone Regeneration Markets
9:10am on Friday 16th of January, 2026 AEDT
Key Points
Equity stake in Marine Biomedical rises from 1.72% to 11.7%
Secures first right of refusal for PearlBone™ distribution globally
PearlBone™ targets US$1.6 billion bone substitute market with FDA 510(k) submission planned by March 2026
Strengthens Orthocell’s regenerative portfolio with bone repair alongside nerve and tendon products
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE